肿瘤治疗患者的QT间期监测及临床风险评估  

QT interval monitoring and clinical risk assessment in patients with cancer therapy

作　　者：成思瑶 耿旭红[1] 潘烁 王莉[1] 王妍 曹友钰 刘彤[3] CHENG Siyao;GENG Xuhong;PAN Shuo;WANG Li;WANG Yan;CAO Youyu;LIU Tong(Department of Function,the Fourth Hospital of Hebei Medical University,Shijiazhuang Hebei 050011;Intelligent ECG Center,Xianyang First People's Hospital,Xianyang Shaanxi 712099;Department of Cardiology,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]河北医科大学第四医院功能科,河北石家庄050011 [2]咸阳市第一人民医院智慧心电中心,陕西咸阳712099 [3]天津医科大学第二医院心脏科,天津300211

出　　处：《实用心电学杂志》2024年第1期8-13,18,共7页Journal of Practical Electrocardiology

基　　金：河北省医学研究课题(20230905)。

摘　　要：目前肿瘤治疗除常规的化疗外,还包括生物靶向治疗、内分泌治疗及免疫检查点抑制剂治疗等。伴随肿瘤治疗出现的心血管不良事件备受关注,其中QT间期延长是与许多肿瘤治疗药物相关的心室复极异常现象,可能会诱发尖端扭转型室性心动过速。目前已知的可影响QT间期的因素包括药物、心率、电解质紊乱等。本文结合国内外新近研究进展,对肿瘤治疗患者QT间期的测量、影响因素,QTc相关不良事件分级,可致QT间期延长的抗肿瘤药物及辅助治疗药物,肿瘤治疗患者QT间期的监测与管理策略进行综述。Besides conventional chemotherapy,cancer therapy also includes bio-targeted therapy,endocrine therapy and immune checkpoint inhibitor therapy and so on at present.Cardiovascular adverse events associated with cancer therapy arouse much attention,among which QT interval prolongation as an abnormal ventricular repolarization phenomenon related to many cancer therapeutic drugs may induce torsades de pointes.Currently known factors that affect QT interval include medications,heart rate,electrolyte disturbances,etc.Based on the latest research progress at home and abroad,this paper reviews the measurement and influencing factors of QT interval,grading of QTc related adverse events,antitumor drugs leading to QT interval prolongation and adjuvant medications,and monitoring and management strategies of QT interval in patients with cancer therapy.

关 键 词：肿瘤 化疗药物 心电图 QT间期 

分 类 号：R540.41[医药卫生—心血管疾病]